MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 597291 | Name: Antineoplaston AS 2-1

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Antineoplaston AS 2-1 is a mixture of sodium salts of phenylacetic acid and phenylacetylglutamine in the ratio 4:1.

Chemical Structure

Antineoplaston AS 2-1
Antineoplaston AS 2-1
CAS#104624-98-8

Theoretical Analysis

MedKoo Cat#: 597291

Name: Antineoplaston AS 2-1

CAS#: 104624-98-8

Chemical Formula: C21H22N2Na2O6

Exact Mass:

Molecular Weight: 444.39

Elemental Analysis: C, 56.76; H, 4.99; N, 6.30; Na, 10.35; O, 21.60

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
104771-87-1 28047-15-6 114-70-5 (Sodium phenylacetate) 103-82-2 (phenylacetic acid) 104624-98-8
Synonym
Antineoplaston AS 2-1; Benzeneacetic acid, sodium salt, mixt. with N2-(phenylacetyl)-L-glutamine monosodium salt;
IUPAC/Chemical Name
sodium (2-phenylacetyl)-L-glutaminate 2-phenylacetate
InChi Key
PFWDHRASWSUTIA-KAFJHEIMSA-L
InChi Code
InChI=1S/C13H16N2O4.C8H8O2.2Na/c14-11(16)7-6-10(13(18)19)15-12(17)8-9-4-2-1-3-5-9;9-8(10)6-7-4-2-1-3-5-7;;/h1-5,10H,6-8H2,(H2,14,16)(H,15,17)(H,18,19);1-5H,6H2,(H,9,10);;/q;;2*+1/p-2/t10-;;;/m0.../s1
SMILES Code
[O-]C([C@H](CCC(N)=O)NC(Cc1ccccc1)=O)=O.O=C([O-])Cc2ccccc2.[Na+].[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 444.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Burzynski SR, Burzynski GS, Janicki TJ, Marszalek A. Complete response and long-term survival (>20 years) of a child with tectal glioma: a case report. Pediatr Neurosurg. 2015;50(2):99-103. doi: 10.1159/000369907. Epub 2015 Apr 22. PubMed PMID: 25926271. 2: Ogata Y, Matono K, Tsuda H, Ushijima M, Uchida S, Akagi Y, Shirouzu K. Randomized phase II study of 5-fluorouracil hepatic arterial infusion with or without antineoplastons as an adjuvant therapy after hepatectomy for liver metastases from colorectal cancer. PLoS One. 2015 Mar 19;10(3):e0120064. doi: 10.1371/journal.pone.0120064. eCollection 2015. PubMed PMID: 25790229; PubMed Central PMCID: PMC4366171. 3: Di Rocco C. Main editor's comment to the paper: the response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Stanislaw R. Burzynski, Tomasz J. Janicki, Gregory S. Burzynski, Ania Marszalek. Childs Nerv Syst. 2014 Dec;30(12):2063. doi: 10.1007/s00381-014-2513-5. Epub 2014 Aug 6. PubMed PMID: 25096071. 4: Massimino M, Clerici CA. Commentary: The response and survival of children with recurrent diffuse intrisic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma, by Burzynski G, et al. Childs Nerv Syst. 2014 Dec;30(12):2065-6. doi: 10.1007/s00381-014-2511-7. Epub 2014 Jul 31. PubMed PMID: 25079885. 5: Burzynski SR, Janicki TJ, Burzynski GS, Marszalek A. The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Childs Nerv Syst. 2014 Dec;30(12):2051-61. doi: 10.1007/s00381-014-2401-z. Epub 2014 Apr 10. PubMed PMID: 24718705; PubMed Central PMCID: PMC4223571. 6: Ushijima M, Ogata Y, Tsuda H, Akagi Y, Matono K, Shirouzu K. Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells. Oncol Rep. 2014 Jan;31(1):19-26. doi: 10.3892/or.2013.2839. Epub 2013 Nov 8. PubMed PMID: 24213840; PubMed Central PMCID: PMC3868501. 7: Burzynski SR. Stanislaw R. Burzynski, MD, PhD: novel cancer research and the fight to prove its worth. Altern Ther Health Med. 2012 May-Jun;18(3):54-61. PubMed PMID: 22875562. 8: Burzynski SR, Janicki TJ, Weaver RA, Burzynski B. Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integr Cancer Ther. 2006 Mar;5(1):40-7. PubMed PMID: 16484713. 9: Burzynski SR, Weaver RA, Janicki T, Szymkowski B, Jurida G, Khan M, Dolgopolov V. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1. Integr Cancer Ther. 2005 Jun;4(2):168-77. PubMed PMID: 15911929. 10: [The regulatory action of dipeptide "Deglutam" on the glutamine metabolized enzymes in the carcinosarcoma SM-1 cells]. Biomed Khim. 2005;51(1):48-52. Russian. PubMed PMID: 15850218. 11: Matono K, Ogata Y, Tsuda H, Araki Y, Shirouzu K. Effects of antineoplaston AS2-1 against post-operative lung metastasis in orthotopically implanted colon cancer in nude rat. Oncol Rep. 2005 Mar;13(3):389-95. PubMed PMID: 15706406. 12: Burzynski SR, Weaver RA, Lewy RI, Janicki TJ, Jurida GF, Szymkowski BG, Khan MI, Bestak M. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report. Drugs R D. 2004;5(6):315-26. PubMed PMID: 15563234. 13: Burzynski SR, Lewy RI, Weaver R, Janicki T, Jurida G, Khan M, Larisma CB, Paszkowiak J, Szymkowski B. Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme. Integr Cancer Ther. 2004 Sep;3(3):257-61. PubMed PMID: 15312271. 14: Hammer MR, Jonas WB. Managing social conflict in complementary and alternative medicine research: the case of antineoplastons. Integr Cancer Ther. 2004 Mar;3(1):59-65. PubMed PMID: 15035877. 15: Ogata Y, Matono K, Shirouzu K. [Anti-proliferative effects of biochemical defense modifier antineoplaston in colorectal carcinoma]. Nihon Rinsho. 2003 Sep;61 Suppl 7:505-9. Japanese. PubMed PMID: 14574945. 16: Burzynski SR, Lewy RI, Weaver RA, Axler ML, Janicki TJ, Jurida GF, Paszkowiak JK, Szymkowski BG, Khan MI, Bestak M. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D. 2003;4(2):91-101. PubMed PMID: 12718563. 17: Tsuda H, Sata M, Kumabe T, Uchida M, Hara H. The preventive effect of antineoplaston AS2-1 on HCC recurrence. Oncol Rep. 2003 Mar-Apr;10(2):391-7. PubMed PMID: 12579278. 18: Tsuda H, Sata M, Ijuuin H, Kumabe T, Uchida M, Ogou Y, Akagi Y, Shirouzu K, Hara H, Nakashima Y. A novel strategy for remission induction and maintenance in cancer therapy. Oncol Rep. 2002 Jan-Feb;9(1):65-8. PubMed PMID: 11748457. 19: Decker GM. Pharmacologic and biologic therapies in cancer care. Clin J Oncol Nurs. 2000 Sep-Oct;4(5):242-4. PubMed PMID: 11111459. 20: Sobczyk W, Piłkowska E, Iwińska-Buksowicz B. [The evaluation of the use of antineoplaston AS2-1 treatment in subacute sclerosing panencephalitis]. Neurol Neurochir Pol. 1999 Jul-Aug;33(4):797-805. Polish. PubMed PMID: 10612094.